Key facts
- Spry Therapeutics’s last known valuation is $63.0M (Jan 2025).
- It has raised $25.0M; the latest was Early Stage VC ($15.0M) in Jan 2025.
- Notable investors include FJ Labs, Pareto Holdings, F-Prime Capital, Eight Roads, Titan Capital — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Spry Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Spry Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Spry Therapeutics
Developer of a digital health platform designed for health professionals to capture and assess patient care data in real time. The company's platform uses machine learning and artificial intelligence to provide patient-specific protocols based on evidence-based practice and standards of care, enabling practitioners and business owners of physical therapy centers to manage all their clinical and administrative functions.
- Sector
- Healthcare
- HQ
- Wilmington, DE, United States
- Founded
- 2021
- Employees
- 170
- Website
- sprypt.com/
- Ownership
- Privately Held (backing)
Spry Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Spry Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Spry Therapeutics in its N-PORT filings yet. We sweep new filings monthly.